“We are trying to maintain patient programs, but we need funding to do it and that is why the walk is so important," said ...

Living with lupus can be overwhelming, says columnist Candace Semien, but it's important to hold tight and fight for yourself ...

For patients with systemic lupus erythematosus (SLE) and pericarditis, recurrence of pericarditis occurs in more than 20% of patients and associated factors include younger age, prednisone treatment, ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

Factors associated with recurrence of pericarditis include younger age, prednisone treatment, active systemic lupus erythematosus, and time since initial episode.

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque ...

Despite advancements in the management of systemic lupus erythematosus (SLE), patients experience poor health-related quality of life (hrQoL) and premature death due to disease severity and treatment ...

A new study sought to identify the frequency and determinants of flares for with people with systemic lupus erythematosus (SLE) with persistently active disease (PAD). Researchers found that both ...

In standing together, we can ensure that Mercédi’s fight with lupus is not her fight alone. A community mobilised by empathy ...

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...